Targeting TIME in Advanced Hepatocellular Carcinoma: Mechanisms of Drug Resistance and Treatment Strategies

Critical Reviews in Oncology/Hematology, Journal Year: 2025, Volume and Issue: unknown, P. 104735 - 104735

Published: April 1, 2025

Language: Английский

---

Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response

Clinical and Molecular Hepatology, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 30, 2024

---

An Early Increase in IL-10 and TNF-α Levels Following Atezolizumab Plus Bevacizumab Treatment Predicts Survival in Advanced Hepatocellular Carcinoma Patients: A Prospective Cohort Study

Cancers, Journal Year: 2024, Volume and Issue: 16(20), P. 3543 - 3543

Published: Oct. 21, 2024

: Reliable biomarkers for predicting outcomes in hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (Ate/Bev) are still lacking. Cytokines, which play a crucial role immune regulation and HCC progression, have potential as predictive markers, but data supporting their use limited. This study aimed to evaluate the impact of early changes cytokine levels on clinical advanced patients.

Language: Английский

---

From biomarker discovery to combined therapies: Advancing hepatocellular carcinoma treatment strategies

World Journal of Gastrointestinal Oncology, Journal Year: 2024, Volume and Issue: 16(11), P. 4518 - 4521

Published: Oct. 25, 2024

This editorial reviews advances in hepatocellular carcinoma (HCC) treatment, focusing on a triple therapy approach and biomarker discovery. Zhang

Language: Английский

---